C.R. Bard, Inc. (BCR) PT Raised to $337.00

C.R. Bard, Inc. (NYSE:BCR) had its price target lifted by Barclays PLC from $245.00 to $337.00 in a research report report published on Monday, November 6th. The firm currently has an equal weight rating on the medical instruments supplier’s stock.

BCR has been the topic of several other research reports. Cowen Inc reiterated a hold rating and issued a $317.00 price target on shares of C.R. Bard in a report on Friday, November 3rd. Zacks Investment Research lowered C.R. Bard from a buy rating to a hold rating in a report on Monday, July 17th. Needham & Company LLC reiterated a hold rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group LLC reiterated a hold rating and issued a $317.00 price target on shares of C.R. Bard in a report on Thursday, September 14th. Finally, BidaskClub lowered C.R. Bard from a strong-buy rating to a buy rating in a report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $303.50.

Shares of C.R. Bard (NYSE:BCR) traded up $0.93 during trading on Monday, hitting $336.11. The company had a trading volume of 173,948 shares, compared to its average volume of 473,005. C.R. Bard has a 52 week low of $206.26 and a 52 week high of $336.98. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The company has a market cap of $24,570.00, a price-to-earnings ratio of 28.94, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53.

C.R. Bard (NYSE:BCR) last announced its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. During the same quarter in the prior year, the company earned $2.64 EPS. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. analysts predict that C.R. Bard will post 11.89 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be paid a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.70%.

In other news, insider Sharon M. Luboff sold 30,252 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $320.00, for a total value of $9,680,640.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David M. Barrett sold 3,344 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 191,593 shares of company stock valued at $62,655,513. Company insiders own 0.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Farallon Capital Management LLC purchased a new stake in shares of C.R. Bard during the second quarter valued at approximately $463,101,000. Renaissance Technologies LLC increased its position in shares of C.R. Bard by 35.4% during the second quarter. Renaissance Technologies LLC now owns 1,295,600 shares of the medical instruments supplier’s stock valued at $409,552,000 after acquiring an additional 338,900 shares during the last quarter. Alpine Associates Management Inc. increased its position in shares of C.R. Bard by 10.0% during the third quarter. Alpine Associates Management Inc. now owns 924,263 shares of the medical instruments supplier’s stock valued at $296,226,000 after acquiring an additional 83,851 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of C.R. Bard by 32.8% during the third quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock valued at $248,607,000 after acquiring an additional 191,443 shares during the last quarter. Finally, Westchester Capital Management LLC increased its position in shares of C.R. Bard by 14.6% during the third quarter. Westchester Capital Management LLC now owns 575,106 shares of the medical instruments supplier’s stock valued at $184,321,000 after acquiring an additional 73,478 shares during the last quarter. 80.31% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/c-r-bard-inc-bcr-given-new-337-00-price-target-at-barclays-plc/1762129.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.